Lung cancer’s symptoms ... Janssen is also looking for collaborators to harness Japanese diagnostic pathology and radiology databases to better understand the genomic and molecular bases ...

Background: Tobacco is considered the most important cause of lung cancer, but other factors could also be involved in its pathogenesis. The aim of the present work was to establish an association ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

The service offers 72-hour access to world-leading cancer specialists, including US' National Comprehensive Cancer Network ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation.

Short-interval CT demonstrated spontaneous resolution of consolidation in more than 50% of lung cancer screening participants, while persistent consolidation showed a 29.8% risk for malignancy.

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term ...

screening and diagnosis such as differentiating lung cancer from tuberculosis, latest updates in pathology, genomics, targeted therapy, and immunotherapy, improving patient advocacy, among others.